A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

Summary

The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emnergize

Timeline

Start

2025-09-16

Primary completion

2027-10-07

Completion

2031-01-23

Drugs

Indications